Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis

Predictors of Success and Relapse After Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06285006

Enrollment

Registered

2024-02-29

Start date

2024-02-23

Completion date

2024-05-12

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturnal Enuresis

Keywords

Nocturnal enuresis, Desmopressin, Monotherapy

Brief summary

Nocturnal Enuresis (NE) is defined as the involuntary passage of urine during sleep past the age of usual control, which is considered a developmental age of 5 to 7 years. NE is a common problem that causes distress to both children and their families. It has an adverse impact on behavior and social life, affects self-esteem, and can result in poor emotional well-being. In Egypt, the prevalence of NE in primary school children is about 15.4%. The family history was seen to have had a markedly significant impact on the occurrence of NE in the studied children. The mainstay of treatment is urotherapy with information and psychoeducation about normal lower urinary tract function, the underlying cause of MNE, disturbed bladder dysfunction in the child with NMNE, and instructions about therapeutic strategies. Alarm therapy and desmopressin are effective in randomized trials. Children with NMNE first need treatment of the underlying daytime functional bladder problem before treatment of nocturnal enuresis.

Interventions

DRUGDesmopressin

Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

7 Years to 14 Years

Healthy volunteers

Inclusion criteria

* School age group (from 7 to 14 years) * Primary monosymptomatic nocturnal enuresis

Exclusion criteria

Patients with one or more of the following will be excluded from the study. * Diurnal enuresis * Urinary tract infection within the preceding 3 months * Diabetes mellitus * History of renal disease, hypertension or genitourinary abnormality, neurological disease, or psychological disease. * Post-micturition residual urine \>1/3 expected bladder capacity. * Each patient will be subjected to the following.

Design outcomes

Primary

Measure	Time frame	Description
The number of episodes per week after desmopressin treatment	After the end of the treatment for one month.	Patients will be evaluate by no. of episodes per week after desmopressin treatment.

Countries

Egypt

Contacts

Primary ContactOmnia Nassar, Dr

omnianassar835@gmail.com01010112054

Backup ContactHosny Elmasry, Prof